1. Home
  2. DOYU vs BDSX Comparison

DOYU vs BDSX Comparison

Compare DOYU & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DouYu International Holdings Limited ADS

DOYU

DouYu International Holdings Limited ADS

HOLD

Current Price

$5.00

Market Cap

153.0M

Sector

Technology

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$15.46

Market Cap

143.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOYU
BDSX
Founded
2014
2005
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Precision Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.0M
143.2M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
DOYU
BDSX
Price
$5.00
$15.46
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$7.00
$32.50
AVG Volume (30 Days)
29.9K
43.2K
Earning Date
05-19-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
N/A
$25.26
Revenue Next Year
N/A
$19.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$4.28
$0.26
52 Week High
$9.34
$20.21

Technical Indicators

Market Signals
Indicator
DOYU
BDSX
Relative Strength Index (RSI) 53.04 54.81
Support Level $4.40 $13.46
Resistance Level $5.05 $16.66
Average True Range (ATR) 0.22 0.95
MACD 0.03 0.06
Stochastic Oscillator 62.66 52.09

Price Performance

Historical Comparison
DOYU
BDSX

About DOYU DouYu International Holdings Limited ADS

DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

Share on Social Networks: